← All trials
NCT06312475
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 9, 2024
- Primary completion
- Oct 15, 2025
- Completion date
- Dec 15, 2025
- First posted
- Mar 15, 2024
- Last posted
- Mar 15, 2024
- Enrollment
- 51
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Alphamab Co., Ltd.Lead sponsor
- Capital Medical UniversityOfficial
- Wenzhou Medical UniversityOfficial
- Jiangxi Provincial People's HospitalOfficial
- Soochow UniversityOfficial
- North China University of Science and Technology Affiliated HospitalOfficial
- Jiao Tong UniversityOfficial
- Central South UniversityOfficial
- Chinese Academy of Medical SciencesOfficial
- Kunming Medical UniversityOfficial
- Southern Medical UniversityOfficial
- Anhui Province Cancer HospitalOfficial
- Henan Medical UniversityOfficial
- LanZhou UniversityOfficial
- China Medical UniversityOfficial
- Jinlin UniversityOfficial
- Sichuan UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.